

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants	:	Mark Tawa et al.	Conf. No.	4554
Serial No.	:	10/541,216	Art Unit:	1617
Filed	:	June 29, 2005	Examiner:	D. Claytor
For	:	PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION		

**CERTIFICATE OF EFS TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office on the date shown below via the "Electronic Filing System" in accordance with 37 C.F.R. § 1.6(a)(4).

Kristin Miele  
Type or print name

/Kristin Miele/  
Signature

July 28, 2009  
Date

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This copy is supplemental to the Information Disclosure Statements filed on November 17, 2006; January 29, 2007; and May 18, 2009.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TP/5013USPCT6/JML.

Respectfully submitted,

Date: July 28, 2009  
TransForm Pharmaceuticals, Inc.  
29 Hartwell Avenue  
Lexington, MA 02421  
Telephone: (732) 524-1106  
Facsimile: (732) 524-5008

By: Jamie M. Larmann/  
Jamie M. Larmann, Patent Attorney  
Reg. No. 48,623  
Customer No. 27777